Rod-cone degeneration (RCD) causes progressive death of photoreceptors with consequent vision loss over many years.[@i1552-5783-60-8-3187-b01] The slowly progressive nature of RCD makes it challenging to reliably monitor changes during a period of 1 or 2 years. In RCD, night vision and peripheral vision are lost earliest, but visual acuity can remain stable and normal until advanced stages of disease.[@i1552-5783-60-8-3187-b01] A longitudinal study of patients with retinitis pigmentosa (RP) followed for 9 years found that visual acuity had the slowest decline relative to other measures, such as visual field area and focal electroretinogram (ERG).[@i1552-5783-60-8-3187-b02] In addition, foveal measures of visual function demonstrate increased variability as retinal degeneration progresses.[@i1552-5783-60-8-3187-b03] Robust, sensitive measures of foveal health and cone loss, particularly ones that rely on structural measures rather than subjective psychophysical measures described above, could facilitate measurement of disease progression in patients with RCD.

Objective measures of retinal structure have become widely used because of advances in noninvasive, high-resolution imaging modalities that can be used to monitor changes in retinal and foveal topography. Spectral-domain optical coherence tomography (SD-OCT), for example, provides noninvasive, cross-sectional measures of retinal structures, including photoreceptors.[@i1552-5783-60-8-3187-b04],[@i1552-5783-60-8-3187-b05] SD-OCT measures of outer retinal thickness have been shown to correlate with visual field sensitivity in eyes with RP,[@i1552-5783-60-8-3187-b06],[@i1552-5783-60-8-3187-b07] and may provide a useful, objective outcome measure for clinical trials.[@i1552-5783-60-8-3187-b04],[@i1552-5783-60-8-3187-b08] Adaptive-optics scanning laser ophthalmoscopy (AOSLO) allows for en face visualization of cone mosaics and measurements of cone spacing and density in healthy and diseased eyes.[@i1552-5783-60-8-3187-b09][@i1552-5783-60-8-3187-b10]--[@i1552-5783-60-8-3187-b11] Modern AOSLO systems are capable of imaging the cone mosaic at the fovea and yield measures of cone spacing[@i1552-5783-60-8-3187-b12][@i1552-5783-60-8-3187-b13][@i1552-5783-60-8-3187-b14][@i1552-5783-60-8-3187-b15][@i1552-5783-60-8-3187-b16][@i1552-5783-60-8-3187-b17]--[@i1552-5783-60-8-3187-b18] that are comparable to histologic studies.[@i1552-5783-60-8-3187-b19]

Objective, structural measures of cone spacing may be more reliable than functional measures, but they are meaningful for patients only if visual function correlates with retinal structure. In cross-sectional studies of RCD patients, increases in cone spacing at or near the fovea were shown to correlate with visual acuity declines in a nonlinear way.[@i1552-5783-60-8-3187-b17],[@i1552-5783-60-8-3187-b18] Visual acuity decreased below 20/25 only in patients whose foveal cone density was 40% to 60% lower than normal, suggesting that visual acuity is preserved despite significant cone loss and is not a sensitive measure of foveal cone integrity.[@i1552-5783-60-8-3187-b17],[@i1552-5783-60-8-3187-b18] One limitation of prior cross-sectional studies, however, was that we could not know the extent to which the low cone densities resulted from actual cone loss or simply reflected the lower end of the spectrum of normal variation in cone density.

To understand how acuity changes during degeneration it would be desirable to track photoreceptor structure and function over time in the same RCD patients. Intervisit and interobserver variability in cone spacing measures from AOSLO images have been quantified in healthy eyes and eyes with RCD; cone changes measured over time that are greater than baseline intervisit and interobserver variability are likely to represent disease progression in RCD patients.[@i1552-5783-60-8-3187-b20] In this retrospective study, we compared foveal cone spacing with best-corrected visual acuity (BCVA) in patients with RCD and healthy subjects monitored longitudinally during periods ranging from 10 months to 5 years to characterize changes in foveal structure and function during disease progression in eyes with RCD.

Methods {#s2}
=======

Study Design {#s2a}
------------

Procedures for this study were followed in accordance with the Declaration of Helsinki, and informed consent was given by all subjects. The study protocol was approved by the institutional review boards of the University of California, San Francisco and the University of California, Berkeley.

Subjects {#s2b}
--------

This retrospective study included healthy adults and patients with RCD, all with visual acuity of 20/40 or better in whom cone mosaics were visualized in the foveal region using AOSLO during two sessions separated by at least 10 months. The subjects are described in the [Table](#i1552-5783-60-8-3187-t01){ref-type="table"}.

###### 

Summary of Clinical Characteristics

  **Patient Information**    **Function**   **Structure**                                                                                                                                                                                            
  ------------------------- -------------- --------------- ---------- ---- -------------------------------------------------------------------------------- -------------- -------------- -------------- ------------- -------------- -------------- ------------
  10046                           OS            22.04       28, 33/F   63  ADRP: NR2E3 p.Gly56 Arg/+                                                         20/25, 20/20      82, 85     0.1, 0         39, 37        2.35, 2.98     0.048, 0.051   71.3, 78.4
  40073                           OD            24.53       32, 35/F   35  ADRP *PRPF31*                                                                     20/16, 20/16      93, 91     −0.1, −0.1     37, 40        1.06, 3.71     0.068, 0.49    77.9, 72.5
                                  OS            24.78                  35  c.239delG, p.?/+ (deletion of G at position -1 in IVS3, affects mRNA splicing)    20/13, 20/16      94, 89     −0.2, −0.1     37, 40        0.88, 1.61     0.074, 0.49    78.2, 75.8
  30019                           OD            22.69       37, 39/F   21  ADRP: *RHO*                                                                       20/16, 20/25      89, 79     −0.1, 0.1      37, 36        1.52, 3.14     0.35, 0.046    67.1, 58.6
                                                                           p.Gly51Val/+                                                                                                                                                              
  40041                           OD            26.58       39, 40/F   13  ARRP                                                                              20/20, 20/20      84, 85     0, 0           39, 39        0.85, 2.13     0.12, 0.34     71.2, 72.8
                                  OS            26.17                  13  *USH2A* p. Cys759Phe/c.8682-3T\>G splice site mutation                            20/25, 20/25      80, 81     0.1, 0.1       40, 39        1.08, 0.82     0.034, 0.048   72.4, 79.2
  30015                           OD            23.96       39, 40/M   13  Simplex RP                                                                        20/20, 20/20      83, 84     0, 0           37, 37        1.56, 2.23     0.21, 0.056    74.4, 70.3
  40026                           OD            22.83       28, 29/F   12  Simplex RP                                                                        20/25, 20/20      83, 84     0.1, 0         32, 33        3.11, 5.23     0.23, 0.098    77.7, 79.8
                                  OS            22.72                      20/20, 20/25                                                                         84, 80         0, 0.1     32, 32         2.39, 4.17    0.072, 0.51    78.3, 75.4     
  40039                           OD            23.35       42, 45/F   36  ARRP                                                                              20/20, 20/16      90, 91     0, −0.1        36, 38        1.97, 2.39     0.073, 0.12    78.3, 71.7
                                  OS            23.24                  36  *USH2A* p. Cys759Phe/ p.Cys766Arg                                                 20/16, 20/16      91, 89     −0.1, −0.1     39, 38        1.77, 0.63     0.053, 0.34    71.2, 78.2
  30013                           OD            23.20       33, 34/M   12  USH2C: *GPR98*                                                                    20/20, 20/16      85, 92     0, −0.1        36, 27        2.12, 2.93     0.045, 0.055   70.1, 64.1
                                                                           p.Thr2875, Lysfs\*2/, p.Met5890, Valfs\*10                                                                                                                                
                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                     
  30007                           OD            22.44       33, 36/F   43  USH3A: *clarin-1*                                                                 20/32, 20/20      74, 85     0.2, 0         38, 35        −0.30, 1.01    0.66, 0.20     78.2, 82.7
                                                                           p.Asn48Lys/                                                                                                                                                               
                                                                           p.Asn48Lys                                                                                                                                                                
  10023                           OD            23.46       57, 58/M   12  Normal                                                                            20/10, 20/13      99, 95     −0.30, −0.19   37, 38        0.98, −0.021   0.034, 0.45    77.4, 69.3
                                  OS            23.27                  12  20/13, 20/10                                                                         98,100      −0.19, −0.30  37, 35         1.50, 0.89    0.16, 0.17     77.5, 77.6     
  10033                           OD            23.91       57, 58 M   10  Normal                                                                            20/16, 20/16      93, 90     −0.1, −0.1     −−, 34        1.70, 1.28     0.045, 0.047   64.5, 64.3
                                  OS            24.03                  12  20/16, 20/20                                                                         93, 85        −0.1, 0     −−, 36         1.00, 1.27    0.051, 0.061   72.1, 67.1     
  40051                           OD            23.74       48, 49/M   12  Normal                                                                            20/13, 20/16      95, 93     −0.19, −0.1    39, 37        0.01, 1.22     0.32, 0.054    76.5, 84.2
                                  OS            23.68                  12  20/13, 20/16                                                                         95, 93      −0.19, −0.1   43, 36         1.54, 1.21    0.039, 0.069   71.7, 72.3     
  40053                           OD            23.74       37, 40/F   37  Normal                                                                            20/20, 20/16      84, 89     0, −0.1        37, 40        0.85, 0.33     0.27, 0.47     75.0, 79.7
                                  OS            24.00                  37  20/13, 20/16                                                                         95, 91      −0.19, −0.1   39, 37         1.15, −0.21   0.20, 0.4      79.8, 78.6     
  40055                           OD            23.96       50, 53/M   35  Normal                                                                            20/13, 20/13      98, 97     −0.19, −0.19   37, 38        −0.14, −0.05   0.41, 0.56     91.8, 86.3
                                  OS            23.87        50, 51    12                                                                                    20/16, 20/16      90, 93     −0.1, −0.1     39, 39        0.21, −0.20    0.22, 0.45     89.3, 83.8
  40054                           OS            25.31        24, 27    36  Normal                                                                            20/16, 20/16      92, 90     −0.1, −0.1     39, 37        0.16, 0.04     0.47, 0.56     84.2, 86.7
  40061                           OS            24.14        50, 53    36  Normal                                                                            20/16, 20/13      93, 95     −0.1, −0.19    38, 37        −0.57, 0.68    0.47, 0.59     77.7, 84.5
  40048                           OD            23.73        51, 53    24  Normal                                                                            20/13, 20/13      95, 95     −0.19, −0.19   38, 36        −0.59, 0.30    0.53, 0.53     86.5, 79.5

Bl, baseline; Fu, follow-up; AD, autosomal dominant; AR, autosomal recessive; USH2C, Usher syndrome type 2C; USH3A, Usher syndrome type 3A. Foveal sensitivity was not measured at baseline in 10033. Both eyes of 40055 were imaged at baseline and 12 months, but the right eye was imaged again at 36 months. For each subject, age is listed in years, and the time between imaging dates 1 and 2 is shown in months.

Functional Measurements {#s2c}
-----------------------

Visual acuity was measured as the number of letters read correctly using standard eye charts, according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol[@i1552-5783-60-8-3187-b21]; results were also converted to the logMAR. Foveal sensitivity was measured in decibels from automated static perimetry measuring macular sensitivity in the central 20° (Humphrey visual field 10-2 protocol; Carl Zeiss Meditech, Dublin, CA, USA).

SD-OCT Imaging and Analysis {#s2d}
---------------------------

SD-OCT images (Spectralis HRA+OCT; Heidelberg Engineering, Vista, CA, USA) were acquired through the foveal center by asking the patient to look at a central fixation target, such that the foveal center on OCT scans included the preferred retinal locus for fixation (PRL). Automated retinal tracking was used to average 100 B-scans in 20° horizontal and vertical cross sections through the PRL. Horizontal SD-OCT scans through the PRL were exported to data analysis software (Igor Pro; WaveMetrics, Inc., Portland, OR, USA) and manually segmented using subroutines[@i1552-5783-60-8-3187-b05],[@i1552-5783-60-8-3187-b06],[@i1552-5783-60-8-3187-b22][@i1552-5783-60-8-3187-b23]--[@i1552-5783-60-8-3187-b24] to identify boundaries between the different retinal layers. The specific measurement made for the purposes of this study was the thickness of the cone outer segment plus RPE (referred to as OS+[@i1552-5783-60-8-3187-b22]) at the PRL defined from AOSLO images as described below.

AOSLO Imaging and Cone Spacing Measurements {#s2e}
-------------------------------------------

Prior to AOSLO imaging, pupils were dilated with 1% tropicamide and 2.5% phenylephrine. High-resolution images of the fovea were acquired using a confocal AOSLO system[@i1552-5783-60-8-3187-b12] and processed into montages as described previously.[@i1552-5783-60-8-3187-b09] The PRL for fixation was localized in the AOSLO images by presenting a target through modulation of the AOSLO scanning raster and 10-second videos were recorded while the patient fixated on the target.[@i1552-5783-60-8-3187-b18] The PRL was computed as the centroid of the scatter plot of the fixated target positions on the retina. AOSLO images that demonstrated clear cone mosaics at or near the PRL were compared with precisely aligned and superimposed SD-OCT scans through the PRL to confirm the cone profiles corresponded to cross-sectional images with visible external limiting membrane and inner segment/outer segment or ellipsoid zone bands, and then were selected for cone spacing. Customized software was used to determine cone spacing using previously described methods.[@i1552-5783-60-8-3187-b09] Other metrics for analyzing cones in AOSLO images that are potentially more sensitive than cone spacing were considered[@i1552-5783-60-8-3187-b25]; however, limited resolution of the AOSLO images acquired near the fovea in this study necessitated the robustness provided by cone spacing. In order to most accurately study the cones involved in fine visual acuity, cone spacing at baseline and subsequent visits at least 10 months later was measured within the region of highest cone resolution and closest to the PRL at each visit. Due to changes in image quality over time, the region of highest cone resolution that permitted reliable cone identification was not always the same at the baseline and follow-up visits. The highest resolution cone spacing location for each visit was measured as an eccentricity in degrees relative to the PRL, because we were unable to identify the exact location of the anatomic fovea (point of maximum cone density). However, this is a small error because the PRL location relative to the point of maximum cone density is reported in the literature to average approximately 35 μm or 7 arcmin.[@i1552-5783-60-8-3187-b16],[@i1552-5783-60-8-3187-b26][@i1552-5783-60-8-3187-b27]--[@i1552-5783-60-8-3187-b28] In this manuscript, we assume that offsets between the PRL and the point of maximum cone density are no different between RCD patients and normal. To account for changes between visits in cone spacing with respect to eccentricity relative to the PRL,[@i1552-5783-60-8-3187-b19] cone spacing values were converted to Z-scores, or the number of standard deviations (SD) from the normal mean (based on 37 age-similar healthy eyes ranging in age from 14--79 years, mean 36.9 years),[@i1552-5783-60-8-3187-b18] at the eccentricity from the PRL where cones were measured. Our decision to do this rested on an assumption that Z-scores and changes in Z-scores at the measured location should reflect similar changes at the PRL. Previous observations of diffuse changes in cone density throughout the central region in RCD patients[@i1552-5783-60-8-3187-b09],[@i1552-5783-60-8-3187-b11],[@i1552-5783-60-8-3187-b17],[@i1552-5783-60-8-3187-b29],[@i1552-5783-60-8-3187-b30] support this assumption. Z-scores between −2 and +2 SD were considered normal; Z-scores greater than 2 indicated increased cone spacing due to cone loss. All measures were acquired at baseline and at least 10 months later in each eye studied.

Statistical Analysis {#s2f}
--------------------

Structural measures (cone-spacing Z-scores and OCT measurement of OS+ thickness at the PRL) were compared with each other using Spearman\'s rank correlation ρ, with 95% confidence intervals that do not contain zero considered statically significant. Structural measures (cone spacing Z-score and OS+ thickness) were compared with functional measures, including ETDRS letters read, logMAR, and foveal sensitivity, at each time point using Spearman\'s rank correlation ρ with 95% confidence intervals, clustered by individual to account for the fact that each individual was measured at baseline and follow-up. The Wilcoxon signed rank test was used to analyze change in measures over time for each subject with *P* \< 0.05 considered statistically significant.

Results {#s3}
=======

Clinical Characteristics {#s3a}
------------------------

Clinical characteristics of the subjects are shown in the [Table](#i1552-5783-60-8-3187-t01){ref-type="table"}. Thirteen eyes from nine patients with RCD were studied. Of 13 eyes, 11 had RP, one had Usher syndrome type 2C, and one had Usher syndrome type 3A. Thirteen eyes of eight healthy subjects were also studied. The nine patients ranged in age from 28 to 42 years at baseline (mean 35), and the eight healthy subjects ranged from 24 to 57 years at baseline (mean 47); the healthy subjects were significantly older than the patients (Wilcoxon rank sum test with continuity correction test *P* = 0.015). AOSLO images were taken at two time points separated by greater than 10 months (mean 765 days, range 311--1935 days) for each of the eyes. There was no significant difference in duration of follow-up between patients and controls (mean follow up in patients = 845.9 days, mean follow-up in healthy subjects = 736.8 days, Wilcoxon test *P* = 0.49).

Structural Measures {#s3b}
-------------------

The PRL was used as the origin to compute the eccentricity of locations where cones were measured and was recorded at each visit. There was slight variation between baseline and follow-up in the precise location of the PRL for each AOSLO image (mean difference = 0.128°, SD = 0.078; average change in patients = 0.120°, SD = 0.088; average change in control subjects = 0.135°, SD = 0.061), which has a minimal effect on the cone spacing Z-score (mean absolute Z-score change due to PRL change = 0.151, range 0.0354--0.368). We attribute the slight change in PRL between visits to a combination of some variability due to the limited 10-second video duration used to assess the PRL and slight image registration errors. [Figure 1](#i1552-5783-60-8-3187-f01){ref-type="fig"} shows examples of foveal cone images near the PRL, the OCT B-scan location and segmentation image, and identification of cones for cone spacing measures in patient 40073; a white circle indicates the center of mass of the displayed fixational eye positions at the PRL. Additional foveal cone images near the PRL for patient 40026 and healthy subject 40051 are shown in [Supplementary Figure S1](#iovs-60-08-12_s01){ref-type="supplementary-material"}. [Figure 2](#i1552-5783-60-8-3187-f02){ref-type="fig"} plots cone spacing Z-scores against the distances from the PRL where measures were made in healthy subjects and patients. The average eccentricities of the cone spacing measures were slightly greater at the second visit than the first visit for both healthy subjects and RCD patients (mean baseline eccentricity = 0.21°, mean follow-up eccentricity = 0.27°; mean difference for normal subjects = 0.06°, 95%CI −0.14 to 0.0010; mean difference for patients = 0.07°, 95%CI −0.19 to 0.054). Note that the Z-scores are greater than 0 for most measurements made closest to the fovea. This is not unexpected in the RCD patients, but in the healthy eyes we might expect the Z-scores to average around 0. The increase in Z-scores here reflects our bias toward selecting healthy eyes with clear and unambiguous cones near the fovea, which in turn are the eyes in which spacing falls in the upper range of the normal distribution. It should be noted that despite the bias, the Z-scores in healthy eyes are all lower than 2 and therefore fall within the normal range ([Fig. 2](#i1552-5783-60-8-3187-f02){ref-type="fig"}). Furthermore, the study focuses on the changes over time, and we have no reason to believe that this selection bias will influence that analysis in any way.

![AOSLO Images of foveal mosaic for RCD patient 40073 at two time points separated by 36 months, with baseline image to the top left (A) and follow-up image to the top right (B). AOSLO images over a larger area are shown at baseline at the bottom left (C) and at follow-up at the bottom right (D) with the green line depicting the location of the SD-OCT B-scan and segmented SD-OCT B-scan shown below. The scale bar is 0.25° and the scales are the same between the two images. The PRL is indicated by the white circle. Insets to the right of each image show the cone locations used to compute cone spacing (red crosses).](i1552-5783-60-8-3187-f01){#i1552-5783-60-8-3187-f01}

![Cone spacing Z-score for all baseline measures shown on the left for normal (Nrm) and RCD patients. Cone spacing Z-score plotted against the distance from the measurement to the AOSLO derived PRL shown in the center. Cone spacing Z-score for all follow-up measures shown on the right. Cone spacing measures taken at baseline are shown as filled symbols and follow-up measures are shown as open symbols; RCD patients are shown as orange squares, healthy subjects are shown as blue circles.](i1552-5783-60-8-3187-f02){#i1552-5783-60-8-3187-f02}

There was a small but significant increase in cone spacing Z-score during follow up in the RCD patients of +0.97 (95%CI 0.57--1.4), while there was no significant change in Z-score in healthy eyes (−0.070, 95%CI −0.41 to 0.27; [Fig. 3](#i1552-5783-60-8-3187-f03){ref-type="fig"}, top). Some patients with the longest follow-up showed little change, while others with shorter follow-up showed greater change, indicating variability in the rate of progression. Changes in cone spacing Z-score for each eye are shown in [Supplementary Figure S2](#iovs-60-08-12_s02){ref-type="supplementary-material"}.

![Change in cone spacing Z-score (top) and change in OS+ thickness (bottom) plotted against the time in months between the first imaging date and second imaging date. RCD patients are shown with orange squares, normal with blue circles. There was a small, significant increase in Z-score in RCD patients (average change = +0.97 \[95%CI 0.57 to 1.4\], while no significant changes were found in healthy subjects (average change = −0.070, 95%CI −0.42 to 0.27). There was no significant change in OS+ thickness in patients with RCD (+0.64 μm, 95%CI −1.9 to 3.2 μm) or healthy subjects (+0.70 μm, 95%CI −1.5 to 3.0 μm).](i1552-5783-60-8-3187-f03){#i1552-5783-60-8-3187-f03}

Mean SD-OCT OS+ thickness at the PRL was not significantly thinner in RCD patients than healthy subjects at baseline or at follow-up (mean difference between healthy and patients at baseline = 4.2 μm, 97.5% CI −0.28 to 8.8 μm; at follow-up = 4.2 μm, 97.5%CI −1.4 to 9.7 μm). SD-OCT OS+ thickness at the PRL did not change significantly during follow-up in healthy eyes (+0.70 μm, 95%CI −1.5 to 3.0 μm, or patients with RCD \[+0.64 μm, −1.9 to 3.2 μm\]; [Fig. 3](#i1552-5783-60-8-3187-f03){ref-type="fig"}, bottom). SD-OCT OS+ thickness at the PRL was negatively correlated with cone spacing Z-score in healthy eyes at baseline (ρ = −0.55, 95%CI −0.86 to −0.031) and at the follow-up exam (ρ = −0.64, 95%CI −0.93 to −0.17). However, in RCD patients OS+ thickness was not correlated with Z-score at baseline (ρ = −0.019, 95%CI −0.55 to 0.47), or follow-up (ρ= −0.011, 95%CI −0.64 to 0.52; [Fig. 4](#i1552-5783-60-8-3187-f04){ref-type="fig"}). When all subjects at all dates were aggregated together there was a significant correlation between OS+ thickness and Z-score (ρ = −0.40, 95%CI −0.67 to −0.087).

![OS+ thickness compared with cone spacing Z-score. Measures taken on first imaging date shown as filled symbols and follow-up shown as open symbols; RCD patients are shown as orange squares, healthy subjects are shown as blue circles. SD-OCT OS+ thickness at the PRL was negatively correlated with cone spacing Z-score in healthy eyes at baseline (ρ = −0.55, 95%CI −0.86 to −0.048) and at the follow-up exam (ρ = −0.64, 95%CI −0.93 to −0.17). However, in RCD patients OS+ thickness was not correlated with Z-score at baseline (ρ = −0.019, 95%CI −0.55 to 0.47) or follow-up (ρ = −0.011, 95%CI −0.64 to 0.52). When all subjects at all dates were aggregated together there was a significant correlation between OS+ thickness and Z-score (ρ = −0.40, 95%CI −0.67 to −0.087).](i1552-5783-60-8-3187-f04){#i1552-5783-60-8-3187-f04}

Functional Measures {#s3c}
-------------------

There was no significant change in visual acuity measured as ETDRS letters read or logMAR or in foveal sensitivity between imaging sessions in the healthy subjects. Despite a significant increase in cone spacing Z-score during follow-up in the RCD patients of +0.97 (see above) there was no significant change in letters read (average change −0.71 letters, 95%CI −2.1 to 0.78), logMAR (average change −0.0074, 95%CI −0.043 to 0.024) or foveal sensitivity (average change −0.36 dB, 95%CI −1.56 to 0.88).

Structure Versus Function {#s3d}
-------------------------

When all study subjects and visits were combined, cone spacing Z-score was significantly correlated with ETDRS letters read (ρ = −0.47, 95%CI −0.67 to −0.24), logMAR (ρ = 0.46, 95%CI 0.26 to 0.66) and foveal sensitivity (ρ = −0.30, 95%CI −0.52 to −0.018; [Fig. 5](#i1552-5783-60-8-3187-f05){ref-type="fig"}). LogMAR is not shown because it is derived from ETDRS letters read. OS+ thickness was not significantly correlated with ETDRS letters read (ρ = −0.11, 95%CI −0.46 to 0.19) or foveal sensitivity when all subjects and visits were combined (ρ = 0.026, 95%CI −0.26 to 0.28; [Fig. 6](#i1552-5783-60-8-3187-f06){ref-type="fig"}).

![Visual acuity shown as ETDRS letters read (top) and foveal sensitivity (bottom) plotted against cone spacing Z-score. The cone spacing and visual acuity measures taken on the first imaging dates are in filled symbols and the second imaging dates are in open symbols; RCD patients are shown as orange squares and healthy subjects shown as blue circles. When all study subjects and visits were combined, cone spacing Z-score was significantly correlated with ETDRS letters read (ρ = −0.47, 95%CI −0.67 to −0.24) and foveal sensitivity (ρ = −0.30, 95%CI −0.52 to −0.018).](i1552-5783-60-8-3187-f05){#i1552-5783-60-8-3187-f05}

![Outer segment plus retinal pigment epithelium and Bruch\'s membrane (OS+) thickness (μm) plotted against visual acuity shown as ETDRS letters read (top) and foveal sensitivity (dB) (bottom). The OS+ and visual acuity measures taken on the first imaging dates are in filled symbols and the second imaging dates are in open symbols; RCD patients are shown as orange squares and healthy subjects shown as blue circles. OS+ thickness was not significantly correlated with ETDRS letters read (ρ = −0.11, 95%CI −0.46 to 0.19) or foveal sensitivity when all subjects and visits were combined (ρ = 0.026, 95%CI −0.26 to 0.28).](i1552-5783-60-8-3187-f06){#i1552-5783-60-8-3187-f06}

Analyzing subgroups and times separately, cone spacing Z-score was significantly correlated with foveal sensitivity at baseline (ρ = −0.55, 95%CI −0.94 to −0.05) but not follow-up (ρ = −0.42, 95%CI −0.77 to 0.084) in RCD patients. In healthy subjects, at baseline there was no significant correlation between Z-score and foveal sensitivity (ρ = 0.15, 95%CI −0.57 to 0.79), but there was a significant correlation at follow-up (ρ = −0.62, 95%CI −0.83 to −0.26).

Discussion {#s4}
==========

This retrospective study is the first to assess longitudinal changes in foveal cone spacing in patients with RCD and healthy eyes followed for at least 10 months, and to relate changes in cone spacing to clinical measures of foveal function and outer retinal thickness. The results represent an important continuation of a prior cross-sectional study in RCD patients that identified a significant, nonlinear correlation between foveal cone spacing and function.[@i1552-5783-60-8-3187-b18] Over the course of the longitudinal study, there was no measurable change in visual function (VA and foveal sensitivity), yet a small but significant amount of cone loss was detected. The increase in cone spacing in RCD patients is consistent with prior reports.[@i1552-5783-60-8-3187-b11] We also confirmed that cone spacing Z-score was correlated with measures of visual function at the fovea.[@i1552-5783-60-8-3187-b18]

The current study expanded our investigation with structural tests by also including OCT. A significant negative correlation between cone spacing Z-score and OS+ thickness at the PRL, where cone spacing increased as OS+ thickness decreased, was found in healthy subjects for both visits, but not at baseline or follow-up visit for RCD patients. The RCD patients in this study varied widely in the type and severity of their disease, which likely resulted in greater variability in the relationship between Z-score and OS+ thickness at the PRL. As seen in [Figure 4](#i1552-5783-60-8-3187-f04){ref-type="fig"}, some patients retained well-preserved outer segments despite increased cone spacing Z-scores. Due to the proximity of the locations measured in the current study to the foveal center, we do not expect rod photoreceptors to have contributed to the OS+ thickness measures.

OS+ thickness was also compared with functional measures but was not significantly correlated with ETDRS letters read or with foveal sensitivity. In contrast, AOSLO-derived cone spacing Z-scores showed significant correlation with both visual acuity and foveal sensitivity.

The lack of a correlation might be real, or it could be that correlation is masked by noise from the measurement itself. While a full assessment of the noise of each measure is beyond the scope of this paper, some discussion of it is warranted. Regarding the functional measures, visual acuity measures are relatively robust (see later discussion on this point), but foveal sensitivity measurements reflect both intratest variability factors, such as neural background noise levels, and intervariability factors, such as reversible ocular and neural fluctuations.[@i1552-5783-60-8-3187-b31],[@i1552-5783-60-8-3187-b32] In addition, foveal sensitivity measures become more variable as visual function decreases. Therefore, RCD patients are more likely to have variable foveal sensitivity measures than the healthy subjects, which may explain why there was no correlation found between cone spacing Z-score and foveal sensitivity at follow-up. Regarding the AOSLO and SD-OCT structural measures, the noise in both measures arises for different reasons. The SD-OCT system has a reported axial resolution of 7 μm and a pixel resolution of 3.5 μm[@i1552-5783-60-8-3187-b33] and the OS+ measurement from the SD-OCT images used in this study comprised between 13 and 23 pixels. The use of a single trained grader (JLD) to manually segment a single horizontal B-scan centered on the PRL provides a further source of imprecision into the OS+ measures in the present study.[@i1552-5783-60-8-3187-b05],[@i1552-5783-60-8-3187-b06],[@i1552-5783-60-8-3187-b22][@i1552-5783-60-8-3187-b23]--[@i1552-5783-60-8-3187-b24] AOSLO images have very fine lateral resolution of 0.58 arcmin (∼2.5 μm) and lateral sampling resolution of 0.14 arcmin/pixel (∼0.7 μm/pixel) but the distance between cones ranges from 3.5 to 7 pixels. These limits to cone spacing measurement are overcome in part by estimates of spacing from a collection of many intercone spacing measures.[@i1552-5783-60-8-3187-b09],[@i1552-5783-60-8-3187-b34] Despite the sources of noise and their impact, the final result was that structural cone measures from AOSLO proved to be more strongly correlated than SD-OCT with visual function in this study.

Limitations {#s4a}
-----------

The present study is limited in the number of eyes imaged with well-resolved cones visible near the fovea and is limited due to the retrospective nature with varied follow-up duration among the subjects. The inclusion of cone spacing measures as far from the PRL as 0.66° was not ideal but was necessary to ensure accurate visualization and measurement of cone spacing due to limited resolution of cones at the foveal center in some eyes. Given that fixation stability generally has a standard deviation of less than 0.1°,[@i1552-5783-60-8-3187-b35] it is likely that in some subjects the cones in the retinal area we measured were never used for the acuity task. The conversion of cone spacing to Z-scores was done to overcome this limitation. Z-scores indicate the deviation in standard deviations from normal and are corrected for eccentricity. In this paper and in previous reports,[@i1552-5783-60-8-3187-b09],[@i1552-5783-60-8-3187-b11],[@i1552-5783-60-8-3187-b36],[@i1552-5783-60-8-3187-b37] we have noted greater than normal spacing and decreased densities throughout the central field of patients with RCD. The decreases in cone density may not be linear (i.e., density loss is greater toward the edges of the remaining visual field), but the degeneration appears to affect the entire retina, including the fovea, in the RCDs we have reported on to date.[@i1552-5783-60-8-3187-b09],[@i1552-5783-60-8-3187-b11],[@i1552-5783-60-8-3187-b36][@i1552-5783-60-8-3187-b37][@i1552-5783-60-8-3187-b38]--[@i1552-5783-60-8-3187-b39] As such, we are confident that cone spacing Z-scores measured close to the fovea reflect cone spacing Z-scores at the fovea.

We chose to study foveal cones and compare with visual acuity even though the cone loss and degeneration---and consequent sensitivity to change---may be greater at the edges of degeneration. Not only did we do this because we were interested in foveal structure and function in these patients, but also because comparing structure and function outside of the fovea can be difficult. It has proven difficult to disambiguate cones and rods from other structures in confocal AOSLO images at the edge of degeneration in RCD patients.[@i1552-5783-60-8-3187-b40] Unfortunately, at the time that these images were collected phase-contrast imaging methods, like split-detector AOSLO[@i1552-5783-60-8-3187-b41] were not available. In addition, whereas visual acuity represents a precise measure of visual function at the PRL and we made cone spacing measures as close as possible to the PRL, we did not have similar confidence that measures of visual function at the peripheral margins of degeneration would represent the function of the cones we quantified.

Finally, the fact that the healthy subjects in the current study were significantly older than the patients could underestimate the differences in cone spacing between healthy and patients, because cone density has been reported to be significantly lower in older, compared with younger, patients.[@i1552-5783-60-8-3187-b42] Thus, our reports of increased cone spacing in the retinal degenerations patients may be considered conservative when compared with significantly older healthy subjects. However, RCD is genetically heterogeneous and it is possible that in some forms of RCD there is nonuniform loss of cones; given the relatively small number of patients in the present study, we cannot compare cone patterns among patients with different genetic forms of retinal degeneration, but this would be an important question to study in future research.

Redundancy in Foveal Cones {#s4b}
--------------------------

Prior studies have suggested that the relationship between foveal structural measures and psychophysical measures is not linear.[@i1552-5783-60-8-3187-b18],[@i1552-5783-60-8-3187-b43] Using a theory that establishes resolvability as a measure directly proportional to the distance between foveal cones with intact connections to higher visual centers, 20/20 vision can be present with loss of 40% of foveal cones, 20/50 vision is expected with 10% of normal foveal cones, and 20/200 is expected with 1% of normal foveal cones.[@i1552-5783-60-8-3187-b43] Recent studies have used AOSLO to measure cone spacing near the fovea in eyes with retinal degeneration and have demonstrated that roughly 50% of cones can be lost before visual acuity declines below 20/25.[@i1552-5783-60-8-3187-b17],[@i1552-5783-60-8-3187-b18] Because clinical visual acuity can remain normal as foveal cone spacing increases, there is likely to be redundancy in foveal cones for high contrast and fine detail visual acuity tasks. The present results provide in vivo, longitudinal data to support predictions that cone density can decrease significantly before it manifests as a measurable decrease in visual acuity.

It is important to note that visual acuity is affected by more than just retinal sampling. Visual acuity integrates everything that occurs along the visual processing pathway, and each stage from where light first enters the eye to the generation of the visual percept can affect it. Moving from low- to high-order effects, the stages that govern visual acuity include (1) blur caused by imperfections in the eye\'s optics (low- and high-order aberrations),[@i1552-5783-60-8-3187-b44] (2) photoreceptor sampling, which is the focus of this study, (3) retinal ganglion cell receptive fields, which are generally considered to not impose a bottleneck for foveal vision in healthy eyes, but remodeling of the retinal in eye disease could change that,[@i1552-5783-60-8-3187-b45] (5) fixational eye movements, which have been shown to confer a benefit to foveal visual acuity,[@i1552-5783-60-8-3187-b46] and finally (6) all the post retinal, neural factors that can limit or interpret the sensory signals that come from the eye. These all need to be considered collectively to fully explain how acuity is preserved despite considerable cone loss.

Subtle Changes Need Finer Tools {#s4c}
-------------------------------

Coupled with the redundancy in foveal cones to buffer the loss of visual impairment in eyes with RCD, the rate of decline in foveal vision in patients with retinal degeneration is slow.[@i1552-5783-60-8-3187-b47][@i1552-5783-60-8-3187-b48]--[@i1552-5783-60-8-3187-b49] Moreover, factors such as the differences in patterns of visual field loss,[@i1552-5783-60-8-3187-b50],[@i1552-5783-60-8-3187-b51] genetic causes of RCD, and environment[@i1552-5783-60-8-3187-b01] may also contribute to variability in the rate of photoreceptor degeneration. Taken together, sensitive, objective measures of photoreceptor survival, such as cone spacing Z-scores from AOSLO images, may be more useful to monitor photoreceptor degeneration at the fovea than standard clinical measures, such as visual acuity, which are insensitive measures of disease progression in RCD. Foveal cone spacing measures may not be the most sensitive measurement of degeneration, especially in patients where cones are lost from the periphery inward; however, foveal cone degeneration will ultimately have the strongest effect on visual function and the patient\'s most precious cones. More sensitive tools may identify significant cone loss before changes in visual acuity and allow for earlier treatment to reduce disease progression as treatments become available. In a study that compared cone spacing in RCD patients treated with sustained-release ciliary neurotrophic factor (CNTF) with sham-treated contralateral eyes, there was a significant increase in cone spacing and a reduction in cone density in the sham-treated RCD eyes, by 2.9% and 9.1%, respectively, over 24 to 36 months.[@i1552-5783-60-8-3187-b11] However, there was no significant change in visual acuity in either the CNTF- or sham-treated eyes.[@i1552-5783-60-8-3187-b11] Not only does this study reinforce the need for sensitive tools to diagnose and track disease progression of RCD but demonstrates the necessity for such tools in following up with treatments in RCD patients.

Conclusions {#s4d}
-----------

This study shows that cone spacing correlated with visual acuity in healthy subjects and RCD patients. However, as cone spacing increased in RCD patients over time, visual acuity did not concurrently change to reflect the progression of disease. Likewise, OS+ thickness did not change over time in RCD patients that demonstrated increased cone spacing, suggesting that cone spacing Z-score measured using adaptive optics ophthalmoscopy may be a more sensitive measure of cone loss at the fovea than measures of visual acuity or OS+ thickness in patients with RCD.
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